What is RXST's current stock price?

RXST (RxSight, Inc.) is currently trading at $5.99 with a market cap of $248.0M.

What sector is RxSight, Inc. in?

RxSight, Inc. (RXST) operates in the Healthcare sector, specifically in the Medical - Devices industry.

Is RXST a good stock to buy?

Analysts have a Hold consensus on RXST with a price target of $10.25. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

RXST RxSight, Inc.

Healthcare

$5.99+0.00%OpenMarket Cap: $248.0M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.94

P/S

1.98

EV/EBITDA

-4.89

DCF Value

$-238.25

FCF Yield

-8.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

77.0%

Operating Margin

-43.4%

Net Margin

-36.6%

ROE

-17.0%

ROA

-15.3%

ROIC

-19.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$30.9M	$-15.9M	$—
Q4 null	$32.6M	$-9.2M	$—
FY null	$134.5M	$-38.9M	$—
Q3 null	$30.3M	$-9.8M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$10.25

Target (Median)

$10.50

Target Range

$9.00 - $11.00

1 Strong Buy0 Buy6 Hold0 Sell2 Strong Sell

Wells FargoEqual Weight

2026-05-07

NeedhamBuy

2026-05-07

StifelHold

2026-03-09

NeedhamBuy

2026-02-26

Piper SandlerNeutral

2026-02-26

Trading Activity

Insider Trades

View All

Goldshleger Ilyaofficer: Chief Operating Officer

SellMon Apr 20

Wilterding Markofficer: Chief Financial Officer

SellTue Mar 03

Wilterding Markofficer: Chief Financial Officer

SellTue Mar 03

Gaines Scottofficer: Chief Customer Officer

SellTue Mar 03

Gaines Scottofficer: Chief Customer Officer

SellTue Mar 03

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

Exchange

—

Beta

1.24

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Peers